The Prognostic Significance of 5-Fluorouracil Induced Inflammation and Immuno-Modulation in Colorectal Cancer Patients

作者: Mona S Abdellateif , Salem E Salem , Doaa M Badr , Sabry Shaarawy , Marwa M Hussein

DOI: 10.2147/JIR.S283069

关键词:

摘要: Aim The change in the levels of peripheral inflammatory markers together with EGFR relation to 5- fluorouracil (5-FU) therapy was evaluated for their prognostic significance colorectal cancer (CRC) patients. Patients and Methods Expression COX2, IL6, IL1β, EGFR, IL10, TNFα were determined quantitative real-time PCR (qPCR) blood 90 CRC response correlated patients' clinical features, disease-free survival (DFS), overall (OS). Results After 6 months 5-FU therapy, increased found be associated smoking, T3 or T4 tumors, performance status (PS) III, positive lymph nodes, distant metastasis, gastrointestinal (GIT) toxicity. combination COX2 interleukins a predictive equation DFS significant patients over-expression EGFR. OS rates reduced expression therapy. Significant hazard disease progression smoking (HR=1.27, P=0.004), induction IL6 (HR=1.35, P=0.001 HR=1.27, P=0.004, respectively). Moreover, TNFα, IL10 are independent factors (P=0.003, 0.003, 0.002, Conclusion effects have shown impact on treatment outcome

参考文章(45)
Mahbuba Rahman, Krithika Selvarajan, Mohammad R Hasan, Annie P Chan, Chaoyang Jin, Jieun Kim, Simon K Chan, Nhu D Le, Young-Bae Kim, Isabella T Tai, None, Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo Neoplasia. ,vol. 14, pp. 624- 633 ,(2012) , 10.1593/NEO.12486
Reyhan Akhtar, Shammy Chandel, Pooja Sarotra, Bikash Medhi, Current status of pharmacological treatment of colorectal cancer. World Journal of Gastrointestinal Oncology. ,vol. 6, pp. 177- 183 ,(2014) , 10.4251/WJGO.V6.I6.177
Zhi-Yuan Chen, Wen-Zhuo He, Li-Xia Peng, Wei-Hua Jia, Rong-Ping Guo, Liang-Ping Xia, Chao-Nan Qian, A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients International Journal of Cancer. ,vol. 136, pp. 584- 592 ,(2014) , 10.1002/IJC.29017
R-D Hofheinz, V Heinemann, L F von Weikersthal, R P Laubender, D Gencer, I Burkholder, A Hochhaus, S Stintzing, Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer British Journal of Cancer. ,vol. 107, pp. 1678- 1683 ,(2012) , 10.1038/BJC.2012.434
Jeffrey A. Jones, Elenir B. C. Avritscher, Catherine D. Cooksley, Marisol Michelet, B. Nebiyou Bekele, Linda S. Elting, Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Supportive Care in Cancer. ,vol. 14, pp. 505- 515 ,(2006) , 10.1007/S00520-006-0055-4
Douglas W. McMillin, Joseph M. Negri, Constantine S. Mitsiades, The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nature Reviews Drug Discovery. ,vol. 12, pp. 217- 228 ,(2013) , 10.1038/NRD3870
A. M. Koorts, P. F. Levay, P. J. Becker, M. Viljoen, Pro- and Anti-Inflammatory Cytokines during Immune Stimulation: Modulation of Iron Status and Red Blood Cell Profile Mediators of Inflammation. ,vol. 2011, pp. 716301- 716301 ,(2011) , 10.1155/2011/716301
Shoshana Zevin, Neal L. Benowitz, Drug interactions with tobacco smoking. An update. Clinical Pharmacokinectics. ,vol. 36, pp. 425- 438 ,(1999) , 10.2165/00003088-199936060-00004
L.M. Soveri, K. Hermunen, A. de Gramont, T. Poussa, E. Quinaux, P. Bono, T. André, P. Österlund, Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? European Journal of Cancer. ,vol. 50, pp. 2966- 2974 ,(2014) , 10.1016/J.EJCA.2014.08.017
Malgorzata Krzystek-Korpacka, Dorota Diakowska, Bartosz Kapturkiewicz, Marek Bębenek, Andrzej Gamian, Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance Cancer Letters. ,vol. 337, pp. 107- 114 ,(2013) , 10.1016/J.CANLET.2013.05.033